Allogeneic Universal Donor TGFβi NK Cell therapy(New Approaches to Neuroblastoma Therapy Consortium)

N/A

Report date: 2025/07/29 20:00:11

Base Information

Drug NameAllogeneic Universal Donor TGFβi NK Cell therapy(New Approaches to Neuroblastoma Therapy Consortium)
Drug Alias NameUniversal Donor (UD) TGFβi NK Cells therapy(New Approaches to Neuroblastoma Therapy Consortium)NANT 2021-01
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNew Approaches To Neuroblastoma Therapy ConsortiumNationwide Children'S HospitalUnited Therapeutics Corp +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesChildren's Neuroblastoma Cancer FundNationwide Children'S HospitalNew Approaches To Neuroblastoma Therapy Consortium +[4] 
Inactive CompaniesN/A
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A